Hyun Chong Woo

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Immunology and Microbiology · Life Sciences

4h-index708citations19works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

interferon and immune responses(11), Cancer Immunotherapy and Biomarkers(8), Virus-based gene therapy research(5), Monoclonal and Polyclonal Antibodies Research(4), RNA modifications and cancer(3)

Publications19 total

Development of a Versatile High-through-put Oligonucleotide LC–MS Method to Accelerate Drug Discovery
AAPS PharmSciTech·2024· 2 cited
Novel approaches and troubleshooting for developing a high-throughput oligonucleotide LC-MS method beyond the current stage
Drug Metabolism and Pharmacokinetics·2024
Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S3 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S3 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
An orally available non-nucleotide STING agonist with antitumor activity
Science·2020· 611 cited
Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)
ACS Medicinal Chemistry Letters·2020· 32 citedOpen Access
Abstract A08: Combination with a novel STING agonist significantly improves efficacy of anti-PD1 therapy in mouse syngeneic tumor models
Cancer Immunology Research·2018
Abstract 4721: Combining STING agonists with an anti-PD-1 antagonist results in marked antitumor activity in immune-excluded tumors
Cancer Research·2018· 6 cited
Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells
Bioconjugate Chemistry·2018· 57 cited

Frequent Co-authors

Ian Knemeyer(16), Bo‐Sheng Pan(15), Samanthi A. Perera(15), Jennifer Piesvaux(15), Jeremy Presland(15), Jared N. Cumming(15), Sašo Čemerski(15), Johnny E. Kopinja(15), Jason Laskey(15), Brian J. Long(15), Ellen C. Minnihan(15), George H. Addona(15), B. Wesley Trotter(14), Sharad Sharma(14), David Jonathan Bennett(14), Kalyan Chakravarthy(14), Archie Tse(14), Yanhong Ma(12), Eric S. Muise(12), Long Cui(12)